Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046858) ANTI-EGFR ANTIBODY DRUG CONJUGATES (ADC) AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046858 International Application No.: PCT/US2018/049409
Publication Date: 07.03.2019 International Filing Date: 04.09.2018
IPC:
A61K 39/395 (2006.01) ,A61K 45/06 (2006.01) ,C07K 16/40 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40
against enzymes
Applicants:
ABBVIE INC. [US/US]; 1 North Waukegan Road North Chicago, IL 60064, US
Inventors:
REILLY, Edward; US
ANDERSON, Mark; US
Priority Data:
62/553,84002.09.2017US
Title (EN) ANTI-EGFR ANTIBODY DRUG CONJUGATES (ADC) AND USES THEREOF
(FR) CONJUGUÉS ANTICORPS ANTI-EGFR-MÉDICAMENT (ADC) ET UTILISATIONS ASSOCIÉES
Abstract:
(EN) The present disclosure provides antibody-drug conjugates (ADCs) comprising a cytotoxic or cytostatic agent linked to an anti-EGFR antibody by way of a linker, compositions comprising the ADCs, methods of making the ADCs, and methods of treating a cancer comprising administering the ADCs to a subject having cancer. The present disclosure provides ADCs that specifically bind EGFR, and in particular human EGFR (hEGFR). The anti-EGFR Ab described herein comprises a S239C mutation in a heavy chain constant region, wherein the numbering is in accordance with Kabat.
(FR) La présente invention concerne des conjugués anticorps-médicament (ADC) comprenant un agent cytotoxique ou cytostatique lié à un anticorps anti-EGFR par l'intermédiaire d'un lieur, des compositions comprenant les ADC, des procédés de préparation des ADC, et des méthodes de traitement d'un cancer comprenant l'administration des ADC à un sujet atteint d'un cancer. La présente invention concerne des ADC qui se lient spécifiquement à l'EGFR, et en particulier à l'EGFR humain (hEGFR). L'anticorps anti-EGFR selon l'invention comprend une mutation S239C dans une région constante de chaîne lourde, la numérotation étant conforme à la numérotation Kabat.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)